15969-46-7

Usage

Structure

It is a heterocyclic organic compound and a derivative of pyrimidine.

Usage in pharmaceuticals and agrochemicals

It is commonly used as a starting material for the synthesis of various pharmaceuticals and agrochemicals.

Sedative and hypnotic properties

Barbituric acid is known for its sedative and hypnotic properties.

Historical use as a central nervous system depressant

It has been used in the past as a central nervous system depressant.

Decline in use

Its use has declined due to the development of safer and more effective alternatives.

Occasional use as a reagent

It is occasionally used as a reagent in organic chemical reactions.

Building block in synthesis

It serves as a building block in the synthesis of other organic compounds.

Stability

The compound is relatively stable and can be handled and stored safely under normal conditions.

Upstream product

• 838-40-4 2,5-diphenyl-1H-pyrrole 
• 75096-77-4 2,5-diphenyl-pyrrol-3-one oxime 
• 41270-99-9 2,6-diphenylpyrimidin-4-ylamine 
• 1670-14-0 benzamidine monohydrochloride 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 29509-91-9 4-chloro-2,6-diphenyl-1,3-pyrimidine 
• 126382-49-8 4-Nitroso-2,6-diphenylpyrimidine 
• 59106-34-2 (E)-ethyl 2-bromo-3-phenylpropenoate 
• 618-39-3 benzamidin 
• 64-17-5 ethanol 
• 7664-41-7 ammonia 
• 2216-94-6 phenylpropynoic acid ethyl ester 
• 106119-62-4 4-Hydroxyamino-2,6-diphenylpyrimidine 
• 100-47-0 benzonitrile 

Downstream Products

• 29509-91-9 4-chloro-2,6-diphenyl-1,3-pyrimidine 
• 29509-92-0 4-chloro-6-methyl-2-phenyl-pyrimidine 
• 90185-70-9 N-(2'-dimethylaminoethyl)-6-methyl-2-phenylpyrimidin-4-amine 
• 90185-74-3 N,N-dimethyl-2-(6'-methyl-2'-phenylpyrimidin-4'-yloxy)ethylamine 
• 90185-66-3 N,N-dimethyl-2-(6'-methyl-2'-phenylpyrimidin-4'-ylthio)ethylamine 
• 90185-72-1 N-(2'-dimethylaminoethyl)-2,6-diphenylpyrimidin-4-amine 
• 90185-76-5 2-(2',6'-diphenylpyrimidin-4'-yloxy)-N,N-dimethylethylamine 
• 901311-75-9 5-chloro-2,4-diphenylpyrimidine 
• 10488-96-7 5-Methyl-2,6-diphenylpyrimidin-4(3H)-one 
• 98-86-2 acetophenone 
• 34672-84-9 1-methoxy-2,2,6,6-tetramethylpiperidine 
• 41062-99-1 5-bromo-6-phenyl-2-phenylpyrimidin-4(3H)-one 
• 737-54-2 6-oxo-2,4-diphenyl-1,6-dihydro-pyrimidine-5-carbonitrile 
• 737-53-1 4-chloro-2,6-diphenylpyrimidine-5-carbonyltrile 

Relevant academic research and scientific papers

2,4,6-Trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists

Adenosine receptor antagonists usually possess a bi- or tricyclic heteroaromatic structure at their core with varying substitution patterns to achieve selectivity and/or greater affinity. Taking into account molecular modeling results from a series of pot

ELECTROACTIVE MATERIALS

There is disclosed a compound which is an N-heterocycle having at least one substituent of Formula (I), In Formula I: Q1, Q2, Q3, Q4, and Q5 are the same or different and can be N or CR1; R1 is the same or different at each occurrenc

Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain

The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (σ1R) antagonists, associated with pharmacological antineuropathic pain activity, are the focus of this article. The new compounds were evaluated in vitro in σ-1 and σ-2 receptor binding assays. The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model. The most promising derivative was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (137), which exhibited a high binding affinity to σ1R receptor (Ki σ1 = 1.06 nM) and good σ-1/2 selectivity (1344-fold). In in vivo tests, compound 137 exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain. In addition, no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted. These data suggest compound 137 may constitute a novel class of drugs for the treatment of neuropathic pain.

A metal-free tandem approach to prepare structurally diverse N-heterocycles: Synthesis of 1,2,4-oxadiazoles and pyrimidinones

A metal-free one-pot approach to the diversity oriented synthesis of N-heterocycles, 1,2,4-oxadiazoles and 2,6 disubstituted pyrimidin-4-ones is described via carboxamidation of amidines with aryl carboxylic acids and aryl propargylic acids. The reactions occur at room temperature forming N-acylamidines which undergo tandem nucleophilic addition-deamination- intramolecular cyclisation to give the corresponding heterocyclic compounds in good to excellent yields. This one pot approach has led to the successful synthesis of the drug lead molecule, ataluren, 3-(5-(2-fluorophenyl)-1,2,4- oxadiazol-3-yl) benzoic acid in two steps. the Partner Organisations 2014.

A phosphine-catalyzed preparation of 4-Arylidene-5-imidazolones

A simple and efficient method for constructing 4-arylidene-5-imidazolones was developed using a phosphinecatalyzed tandem umpolung addition and intramolecular cyclization of amidine pronucleophiles on arylpropiolates. The reaction offers a robust route to heterocycle analogues of the fluorescent protein chromophores. (Chemical Equation Presented).

Aminopyrimidinone Cdc7 Kinase Inhibitors

We have investigated the SAR of a series of pyrimidinone-containing Cdc7 kinase inhibitors. A wide range of amine substitutions give potent compounds with activities (Ki) less than 1 nM. Kinase selectivity is reasonable and cytotoxicity corresponds to inhibition of MCM2 phosphorylation.

A facile synthesis of pyrimidin-4-ones

A facile synthesis of 2,6-disubstituted pyrimidin-4-ones and 2,5,6-trisubstituted pyrimidin-4-ones from commercially available materials with application of microwave technology in key steps is described.

PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS

Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.

A convenient synthesis of 5- and 6-substituted 2-phenyl-3H-pyrimidin-4-ones

A simple and convenient one-pot procedure for the synthesis of 5- and 6-substituted 2-phenyl-3H-pyrimidin-4-ones by the condensation of 4-alkoxy-1,1,1-trichloroalk-3-en-2-ones with benzamidine hydrochloride is described. Georg Thieme Verlag Stuttgart.

NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan.